Digene Stock Rebound Could Continue In 2005; OTC Index Ahead 23%
This article was originally published in The Gray Sheet
Executive Summary
Digene's increased focus on physician detailing for its DNAwithPap human papillomavirus test, coupled with plans for consumer advertising, could allow the firm to exceed recently revised growth expectations